AbbVie Inc.
ABBV · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $56,334 | $54,318 | $58,054 | $56,197 |
| % Growth | 3.7% | -6.4% | 3.3% | – |
| Cost of Goods Sold | $16,904 | $20,415 | $17,414 | $17,446 |
| Gross Profit | $39,430 | $33,903 | $40,640 | $38,751 |
| % Margin | 70% | 62.4% | 70% | 69% |
| R&D Expenses | $12,791 | $7,675 | $6,510 | $8,046 |
| G&A Expenses | $11,089 | $10,704 | $13,260 | $10,249 |
| SG&A Expenses | $13,189 | $12,872 | $15,260 | $12,349 |
| Sales & Mktg Exp. | $2,100 | $2,200 | $2,000 | $2,100 |
| Other Operating Expenses | $4,313 | $599 | $753 | $432 |
| Operating Expenses | $30,293 | $21,146 | $22,523 | $20,827 |
| Operating Income | $9,137 | $12,757 | $18,117 | $17,924 |
| % Margin | 16.2% | 23.5% | 31.2% | 31.9% |
| Other Income/Exp. Net | -$5,421 | -$6,507 | -$4,640 | -$4,935 |
| Pre-Tax Income | $3,716 | $6,250 | $13,477 | $12,989 |
| Tax Expense | -$570 | $1,377 | $1,632 | $1,440 |
| Net Income | $4,278 | $4,863 | $11,836 | $11,542 |
| % Margin | 7.6% | 9% | 20.4% | 20.5% |
| EPS | 2.4 | 2.73 | 6.65 | 6.48 |
| % Growth | -12.1% | -58.9% | 2.6% | – |
| EPS Diluted | 2.39 | 2.72 | 6.63 | 6.45 |
| Weighted Avg Shares Out | 1,769 | 1,768 | 1,771 | 1,770 |
| Weighted Avg Shares Out Dil | 1,773 | 1,773 | 1,778 | 1,777 |
| Supplemental Information | – | – | – | – |
| Interest Income | $648 | $540 | $186 | $39 |
| Interest Expense | $2,808 | $2,224 | $2,230 | $2,423 |
| Depreciation & Amortization | $8,386 | $8,698 | $8,467 | $8,521 |
| EBITDA | $14,910 | $17,172 | $24,174 | $23,933 |
| % Margin | 26.5% | 31.6% | 41.6% | 42.6% |